Predicted protein targets (top 2)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 2/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7641299 | 0.86 | CA2 (0.35) | CA2MAPT | |
| SCHEMBL4368056 | 0.86 | CA2 (0.35) | CA2MAPT | |
| SCHEMBL18394413 | 0.86 | CA2 (0.35) | CA2MAPT | |
| SCHEMBL4915438 | 0.86 | CA2 (0.35) | CA2MAPT | |
| SCHEMBL6573945 | 0.86 | CA2 (0.35) | CA2MAPT | |
| SCHEMBL23518789 | 0.86 | CA2 (0.35) | CA2MAPT | |
| SCHEMBL15489117 | 0.86 | CA2 (0.35) | CA2MAPT | |
| SCHEMBL4915430 | 0.86 | CA2 (0.35) | CA2MAPT | |
| SCHEMBL7090127 | 0.84 | GAA (0.39) | CA2MAPT | |
| SCHEMBL7213941 | 0.80 | CA2 (0.43) | CA2MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1457495-A1 | Adenosine A1 receptor agonists | GLAXO GROUP LIMITED (GB) | 2004-09-15 | — | — | EP | disclosed |
| EP-1030857-B1 | ADENOSINE A1 RECEPTOR AGONISTS | GLAXO GROUP LTD (GB) | 2004-08-18 | — | — | EP | disclosed |
| US-6677316-B2 | TREATING ISCHEMIA, CARDIOVASCULAR DISORDERS, STROKE, PAIN, NERVOUS SYSTEM DISORDERS OR SLEEP APNEA; ADENOSINE A1 RECEPTOR AGONIST; 2-(3-(TERT-BUTYL)-1,2,4-OXADIAZOL-5-YL)-5-(6-(ISOBUTYLAMINO)-9H-PURIN-9-YL) TETRAHYDROFURAN-3,4-DIOL | SMITHKLINE BEECHAM CORPORATION | 2004-01-13 | — | — | US | disclosed |
| US-20030096788-A1 | Adenosine derivatives | GLAXO WELLCOME INC. | 2003-05-22 | — | — | US | disclosed |
| US-6455510-B1 | Chemical Compounds | SMITHKLINE BEECHAM CORPORATION | 2002-09-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030096788-A1 | Adenosine derivatives | ADORA3, ADORA2A, ADORA1 | CA2 3276/4885MAPT 4303/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.